REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Binds Bacterium Or Component Thereof Or Substance Produced By Said BacteriumBinds Bacterium Or Component Thereof Or Substance Produced By Said Bacterium patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178111 - Identification and application of antibiotic synergy The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a β-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, ... 08/02/07 - 20070178110 - Surface-located campylobacter jejuni polypeptides The present invention relates to surface-located polypeptides of Campylobacter jejuni and their use in vaccination against Campylobacter. The invention furthermore relates to the use in vaccination of polynucleotides, expression vectors, recombinant viruses or recombinant cells expressing these surface-located polypeptides. Moreover, the invention relates to the use of antibodies against the ... 07/19/07 - 20070166315 - Vibrio cholerae o139 conjugate vaccines The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae ... 05/10/07 - 20070104722 - Targeted biocides The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate ... 03/22/07 - 20070065453 - Transferrin-binding proteins from neisseria gonorrhoeae and neisseria meningitidis Iron-regulated, outer membrane proteins found in Neisseria gonorrhoeae and Neisseria meningitidis are important in transferrin receptor function. The proteins, which are isolatable by means of a transferrin affinity column, bind specifically to antisera raised against an iron-regulated outer membrane protein having a molecular weight of approximately 100 kD found in ... 03/08/07 - 20070053917 - Composition and method for the treatment and prevention of enteric bacterial infections The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a ... 01/25/07 - 20070020281 - Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof The present invention relates to peptides that bind to the bacterial spores, such as B. anthracis, B. subtilis and B. cereus spores. The present invention also relates to method of identifying such peptides using phage display ligand screening system. The present invention further relates to the use of such peptides ... 01/04/07 - 20070003560 - Humanized monoclonal antibodies that protect against shiga toxin induced disease The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment ... 12/28/06 - 20060292162 - Plasma or serum fraction for the treatment or prevention of bacterial infections The present invention relates to a plasma or serum fraction derived from a mammal exposed to an inoculant (e.g., a bacteria-bearing inoculant), which fraction has been depleted of one or more high molecular weight proteins or biological agents present in the unprocessed plasma or serum, as well as to a ... 12/28/06 - 20060292161 - Protective epitopes of adenyl cyclase-haemolysin (ac-hly), their application to the treatment or to the prevention of bordetella infections Purified nucleic acids comprising a nucleotide sequence encoding an immunogenic polypeptide of adenyl cyclase-haemolysin (AC-Hly), which induces formation of protective antibodies against an infection by a bacteria selected from the group consisting of B. pertussis, B. parapertussis, and B. bronchiseptica when the nucleic acid or polypeptide is administered to a ... 12/07/06 - 20060275310 - Method and detection and decontamination of antigens by nanoparticle-raman spectroscopy A composition and method of detecting antigens and killing bacteria and virus is described. The composition and method comprise a fluorescent nanoparticle conjugated to a substance capable of binding specifically to a antigen and exposing the location containing the fluorescent nanoparticle and antigen to a wavelength of light capable of ... 11/02/06 - 20060246079 - Neutralizing human antibodies to anthrax toxin A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method ... 10/26/06 - 20060240029 - Chlamydia pneumoniae antigens The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from C. pneumoniae, methods for isolating such antigens and specific uses thereof. ... 10/12/06 - 20060228368 - Method of protecting against staphylococcal infection A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate the 336 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, ... 10/05/06 - 20060222650 - Broad spectrum pyrogenic antagonists and vaccines directed against pyrogenic exotoxins The invention relates to peptides comprising an amino acid sequence homologous to the amino sequence of a fragment of a pyrogenic exotoxin, and functional derivatives of said peptides, capable of eliciting protective immunity against toxic shock induced by a pyrogenic exotoxin or by a mixture of pyrogenic exotoxins. Preferred peptides ... 09/07/06 - 20060198849 - Preparation method of igy for preventing and cure mouth disease and the toothpaste base on the igy The present invention relates to a preparation method of IgY for preventing and cure mouth disease, and a safe toothpaste containing the IgY. ... 08/31/06 - 20060193866 - H pylori antigens The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from H. pylori, methods for isolating such antigens and specific uses thereof. ... 07/27/06 - 20060165704 - Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to ... 07/13/06 - 20060153856 - P. aeruginosa mucoid exopolysaccharide specific binding peptides The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic ... 06/08/06 - 20060121045 - Antibody fragments for protection from pathogen infection and methods of use thereof Methods and compositions are provided for an antibody fragment or functional fragment thereof, which fragments do not contain an Fc region. The invention also describes in vitro and in vivo treatment of a subject exposed to a pathogen, pathogen infection, or pathogen protein product by administering to the subject a ... 05/04/06 - 20060093609 - Vaccine against yersinia comprising one or two antibodies, one specific for yersinia pestis f1-antigen and the other one for yersinia pestis v-antigen The use of (i) an antibody specific for Yersinia pestis F1-antigen, or a binding fragment thereof, or (ii) an antibody specific for Yersinia pestis V-antigen, or a binding fragment thereof, or a combination of (i) and (ii), in the production of a medicament for the treatment of infection by Yersinia ... 04/20/06 - 20060083746 - Receptor for b. anthracis toxin The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the polynucleotides and polypeptides, host cells containing related polynucleotide molecules, and cells displaying no anthrax toxin receptor on an exterior surface of the cells-minus cell lines and ... 01/05/06 - 20060002939 - Vaccines, methods, and antibodies specific for lipoteichoic acid of gram positive bacteria The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and ... 12/29/05 - 20050287149 - Human monoclonal antibodies against bacillus anthracis protective antigen Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human ... 12/22/05 - 20050281830 - Detection, prevention, and treatment systems for anthrax A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method ... 10/06/05 - 20050220797 - Prophylactic and therapeutic monoclonal antibodies In this application are described monoclonal antibodies which specifically recognize V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment ... 09/29/05 - 20050214306 - Surface proteins of leptospira The invention relates to Leptospiral surface proteins, and the nucleic acid molecules which encode them. Various uses are described, including immunoprophylactic, diagnostic and therapeutic methods. ... ### FreshPatents.com Support |